BIOFIRST CORPORATION

ABVC BioPharma Receives $150K Milestone Payment, Advancing Botanical CNS Therapies Through Strategic Partnerships

- ABVC BioPharma received a $150,000 milestone payment from AiBtl BioPharma, bringing total licensing revenue to $846,000 across strategic partnerships. - The company's botanical drug candidates ABV-1504 and ABV-1505 for major depressive disorder and ADHD have completed Phase II trials and hold active FDA INDs. - ABVC's licensing-first strategy has generated non-dilutive revenue while positioning the company as a leader in CNS-focused botanical therapeutics. - The partnership addresses growing global demand for alternative CNS treatments, with Australia facing drug shortages affecting nearly 300,000 patients.